Please try another search
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Name | Age | Since | Title |
---|---|---|---|
Gyo Sagara | - | 2008 | CEO, President & Representative Director |
Yasuo Hishiyama | 50 | 2016 | Outside Audit & Supervisory Board Member |
Akiko Tanabe | 53 | 2020 | Outside Audit & Supervisory Board Member |
Hironobu Tanisaka | 62 | 2021 | Outside Audit Supervisory Board Member |
Toshihiro Tsujinaka | 59 | 2016 | Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director |
Katsuyoshi Nishimura | 69 | 2011 | Chairman of Audit & Supervisory Board |
Shusaku Nagae | 73 | 2021 | Independent Outside Director |
Toichi Takino | 55 | 2020 | Senior Managing Executive Officer, Head of Research Division & Director |
Kiyoaki Idemitsu | 59 | 2021 | Managing Executive Officer, GM of Development Division & Director |
Masao Nomura | 74 | 2018 | Independent Outside Director |
Akiko Okuno | 53 | 2020 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review